Traitement chirurgical à; visée curatrice des carcinoses péritonéales

Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer

“…The trend towards lower clearance with an increasing cisplatin dose (−5.4/10 mg/m2) was not significant (p = 0.26). No significant association was observed between the creatinine level and body mass index (p = 0.77), Sugarbaker's peritoneal cancer index (p = 0.41), maintenance fluid requirement and blood loss during surgery (p = 0.41 and 0.80, respectively, details in Appendix A Table 5) [16].…”

Transitory Stoma at the Time of Complete Cytoreductive Surgery Affects Survival for Patients with Advanced-stage Ovarian Cancer

“…From 2006 to 2011, 237 patients with stage IIIB to IVA ovarian cancer had undergone CRS (CC0 according to the Sugarbaker Classification) in our institution (13). Among them, 99 patients had undergone a low anterior resection without TPS and nine with a TPS.…”

“…From our Institution, we retrospectively selected patients treated for ovarian cancer from 2006 to 2011 with the following criteria: stage IIIB to IV ovarian cancer according the International Federation of Gynecology and Obstetrics classification (3); CRS (CC0 according to Sugarbaker's classification); a low anterior resection with or without another bowel resection (13).…”